nach oben

Erschienen in:

18.09.2017 | Nierenkarzinom | fortbildung

Konzept mit Geschichte

Immuntherapie urologischer Tumoren

verfasst von: Dr. med. Christoph-Alexander J. von Klot, Markus A. Kuczyk

Erschienen in: InFo Hämatologie + Onkologie | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Immuntherapeutische Konzepte haben in der urologischen Onkologie Tradition. Im Vergleich zur Chemotherapie besteht der Vorteil moderner Immuntherapeutika vor allem in einem günstigeren Nebenwirkungsprofil und einem längeren Ansprechen. Der Umgang mit Toxizitäten und Phänomenen wie der Pseudoprogression bleiben gleichwohl Herausforderungen.

Morales A et al. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.PubMedCrossRef

Böhle A, Bock. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. PR Urology. 2004;63(4):682–6; discussion 686-7.CrossRef

Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.PubMedCrossRef

Franklin JR et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol. 1996;14(4):230–6.PubMed

Sarna G et al. Interferon in renal cell carcinoma. The UCLA experience. Cancer. 1987;59(3 Suppl):610–2.PubMedCrossRef

Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958–62.

Zhang YQ et al. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses. Int Immunol. 1997;9(8):1095–102.CrossRef

Baumeister SH et al. Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016;34:539–73.PubMedCrossRef

Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015;7(6):365–77.PubMedPubMedCentralCrossRef

10.

Fisher R et al. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2013;23(1):38–45.PubMedCrossRef

11.

Kroeger N et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014 Jun;65(6):1086–92.PubMedCrossRef

12.

Yang JC et al. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis. J Immunother. 2007;30(8):825–30.PubMedPubMedCentralCrossRef

13.

Motzer RJ et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–13.PubMedCrossRef

14.

Hutson TE et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14(13):1287–94.PubMedCrossRef

15.

Choueiri TK et al. First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): results from a phase Ib trial. J Clin Oncol. 2017;35(Suppl):Abstr 4504.

16.

Atkins MB et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 2017;35(Suppl):Abstr 4505.

17.

Bellmunt J et al. Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract. J Clin Oncol. 2009;27(27):4454–61.PubMedCrossRef

18.

Balar AV et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.PubMedCrossRef

19.

Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.PubMedPubMedCentralCrossRef

20.

http://www.roche.com/media/store/releases/med-cor-2017-05-10.htm

21.

Sharma P et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;8(3):312–22.CrossRef

22.

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01693562

23.

Bellmunt J et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015–26.PubMedCrossRef

24.

Bajorin DF et al. Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). J Clin Oncol. 2017;35(Suppl):Abstr 4501.

25.

Balar AV et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. J Clin Oncol. 2017;35( Suppl 6S):Abstr 284.CrossRef

26.

O’Donnell PH et al. Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol. 2017;35(Suppl):Abstr 4502.

27.

De Santis M et al. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. J Clin Oncol. 2012;30(2):191–9.

28.

De Santis M et al. Vinfluninegemcitabine versus vinfluninecarboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016;27(3):449–54.PubMedCrossRef

29.

Ryan CJ et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.PubMedCrossRef

30.

Kwon ED et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12.PubMedPubMedCentralCrossRef

31.

Beer TM et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol: 2017;35(1):40–7.PubMedCrossRef

32.

Hussein M-RA et al. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol. 2009;86(2):108–13.PubMedCrossRef

33.

Fankhauser CD et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer 2015;113(3):411–3.PubMedPubMedCentralCrossRef

34.

Tobias-Machado M et al. Video Endoscopic Inguinal Lymphadenectomy: A New Minimally Invasive Procedure for Radical Management of Inguinal Nodes in Patients With Penile Squamous Cell Carcinoma. J Urol. 2007;177(3):953–8.PubMedCrossRef

35.

Di Lorenzo G et al. Paclitaxel in pretreated metastatic penile cancer: Final results of a phase 2 study. Eur Urol. 2011;60(6):1280–4.PubMedCrossRef

36.

Hammers HJ et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017:JCO2016721985. [Epub ahead of print].

37.

Spain L et al. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.PubMedCrossRef

38.

Läubli H et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer. 2017;5(1):46.PubMedPubMedCentralCrossRef

39.

Von Der Maase H et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.PubMedCrossRef

40.

Powles T et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.PubMedCrossRef

41.

Dong H et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.PubMed

42.

Grosso J et al. Programmed death-ligand 1 (PD-L1) expression in various tumor types. Journal for ImmunoTherapy of Cancer. 2013;1(Suppl 1):P53.PubMedCentralCrossRef

43.

Loi S et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50.PubMedCrossRef

44.

Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19(5): 1021–34.PubMedPubMedCentralCrossRef

45.

Heynckes S et al. Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget. 2017 Jun 28 [Epub ahead of print].

46.

Sharpe AH et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239–45.PubMedCrossRef

47.

Barsoum IB et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74(3):665–74.PubMedCrossRef

48.

Eisenhauer EA et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef

49.

Wolchok JD et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.PubMedCrossRef

50.

George S et al. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. JAMA Oncol. 2016;2(9):1179–86.PubMedPubMedCentralCrossRef

51.

Escudier B et al. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol. 2017;72(3):368–76.PubMedCrossRef

Titel: Konzept mit Geschichte
Immuntherapie urologischer Tumoren
verfasst von: Dr. med. Christoph-Alexander J. von Klot
Markus A. Kuczyk
Publikationsdatum: 18.09.2017
Verlag: Springer Medizin
Schlagwörter: Nierenkarzinom
Zytostatische Therapie
Nierenkarzinom
Nierenkarzinom
Urothelkarzinom
Urothelkarzinom
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe Sonderheft 1/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-017-5790-9

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Immuntherapie urologischer Tumoren

Zusammenfassung

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2017

Status quo und ein Blick in die Zukunft

CTL019-Therapie beim DLBCL

SLAMF7-Antikörper beim multiplen Myelom

PD-1-Blockade zeigt Erfolge

Immuntherapie von akuten Leukämien: immer mehr Optionen

Immuntherapie beim Hodgkin-Lymphom

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie